Ghent University Academic Bibliography

Advanced

Vindesine-ifosfamide-platinum (VIP) induction chemotherapy in surgically staged IIIA-N2 non-small-cell lung cancer: a prospective study

JF Vansteenkiste, PR De Leyn, GJ Deneffe, Yolande Lievens UGent, KL Nackaerts, DE Van Raemdonck, E van der Schueren, TE Lerut and MG Demedts (1998) ANNALS OF ONCOLOGY. 9(3). p.261-267
abstract
Purpose. In the pioneer data from the Memorial-Sloan-Kettering group, preoperative mitomycin-C-vindesine--platinum (MVP) induction chemotherapy in N2-NSCLC was accompanied with substantial pulmonary toxicity. In this study, the efficacy and toxicity of three-drug VIP induction chemotherapy, the pathologic response in resection specimens, the early survival and relapse patterns are examined. Patients and methods: Between June 1995 and March 1997, 39 consecutive patients with pathology proven N2-NSCLC were treated with three cycles of VIP induction, followed by definitive locoregional treatment (resection and mediastinal dissection or radical radiotherapy). Several patients had unfavorable prognostic characteristics with respect to clinical and biological findings, tumor location and bulk of disease. Results. The response rate to chemotherapy was 59% (95% Confidence Interval 34-75). Twenty-three responding patients had radical locoregional treatment: radical radiotherapy in four, resection in 19. Downstaging was present in nine of the 19 resection specimens, with two pathologic complete responses. The median survival time (MST) of all patients is 19 months, with a projected two-year survival of 49%. In patients responsive to chemotherapy who received definitive local treatment, the MST is not yet reached, and the projected two-year survival is 57%. Relapses were mainly distant, with isolated brain relapse as a disturbing finding. The main toxicity's were leukopenia. and vomiting, but they were manageable. In contrast with MVP no severe pulmonary toxicity occurred. Conclusions:. VIP is a suitable induction regimen for NSCLC, demonstrating a good activity and very acceptable toxicity.
Please use this url to cite or link to this publication:
author
organization
year
type
journalArticle (original)
publication status
published
subject
keyword
MITOMYCIN-C, CISPLATIN, RANDOMIZED TRIAL, PREOPERATIVE CHEMOTHERAPY, GROUP-B PROTOCOL-8935, N2-disease, non-small-cell lung carcinoma, lung surgery, induction chemotherapy, combined modality treatment, NODES, CARCINOMA, REGIMENS, MEDIASTINOSCOPY, N2
journal title
ANNALS OF ONCOLOGY
Ann. Oncol.
volume
9
issue
3
pages
261 - 267
Web of Science type
Article
Web of Science id
000074449000012
ISSN
0923-7534
DOI
10.1023/A:1008240127706
language
English
UGent publication?
no
classification
A1
copyright statement
I have transferred the copyright for this publication to the publisher
id
3172156
handle
http://hdl.handle.net/1854/LU-3172156
date created
2013-03-22 15:34:19
date last changed
2016-12-19 15:45:59
@article{3172156,
  abstract     = {Purpose. In the pioneer data from the Memorial-Sloan-Kettering group, preoperative mitomycin-C-vindesine--platinum (MVP) induction chemotherapy in N2-NSCLC was accompanied with substantial pulmonary toxicity. In this study, the efficacy and toxicity of three-drug VIP induction chemotherapy, the pathologic response in resection specimens, the early survival and relapse patterns are examined. 
Patients and methods: Between June 1995 and March 1997, 39 consecutive patients with pathology proven N2-NSCLC were treated with three cycles of VIP induction, followed by definitive locoregional treatment (resection and mediastinal dissection or radical radiotherapy). Several patients had unfavorable prognostic characteristics with respect to clinical and biological findings, tumor location and bulk of disease. 
Results. The response rate to chemotherapy was 59\% (95\% Confidence Interval 34-75). Twenty-three responding patients had radical locoregional treatment: radical radiotherapy in four, resection in 19. Downstaging was present in nine of the 19 resection specimens, with two pathologic complete responses. The median survival time (MST) of all patients is 19 months, with a projected two-year survival of 49\%. In patients responsive to chemotherapy who received definitive local treatment, the MST is not yet reached, and the projected two-year survival is 57\%. Relapses were mainly distant, with isolated brain relapse as a disturbing finding. The main toxicity's were leukopenia. and vomiting, but they were manageable. In contrast with MVP no severe pulmonary toxicity occurred. 
Conclusions:. VIP is a suitable induction regimen for NSCLC, demonstrating a good activity and very acceptable toxicity.},
  author       = {Vansteenkiste, JF and De Leyn, PR and Deneffe, GJ and Lievens, Yolande and Nackaerts, KL and Van Raemdonck, DE and van der Schueren, E and Lerut, TE and Demedts, MG},
  issn         = {0923-7534},
  journal      = {ANNALS OF ONCOLOGY},
  keyword      = {MITOMYCIN-C,CISPLATIN,RANDOMIZED TRIAL,PREOPERATIVE CHEMOTHERAPY,GROUP-B PROTOCOL-8935,N2-disease,non-small-cell lung carcinoma,lung surgery,induction chemotherapy,combined modality treatment,NODES,CARCINOMA,REGIMENS,MEDIASTINOSCOPY,N2},
  language     = {eng},
  number       = {3},
  pages        = {261--267},
  title        = {Vindesine-ifosfamide-platinum (VIP) induction chemotherapy in surgically staged IIIA-N2 non-small-cell lung cancer: a prospective study},
  url          = {http://dx.doi.org/10.1023/A:1008240127706},
  volume       = {9},
  year         = {1998},
}

Chicago
Vansteenkiste, JF, PR De Leyn, GJ Deneffe, Yolande Lievens, KL Nackaerts, DE Van Raemdonck, E van der Schueren, TE Lerut, and MG Demedts. 1998. “Vindesine-ifosfamide-platinum (VIP) Induction Chemotherapy in Surgically Staged IIIA-N2 Non-small-cell Lung Cancer: a Prospective Study.” Annals of Oncology 9 (3): 261–267.
APA
Vansteenkiste, JF, De Leyn, P., Deneffe, G., Lievens, Y., Nackaerts, K., Van Raemdonck, D., van der Schueren, E., et al. (1998). Vindesine-ifosfamide-platinum (VIP) induction chemotherapy in surgically staged IIIA-N2 non-small-cell lung cancer: a prospective study. ANNALS OF ONCOLOGY, 9(3), 261–267.
Vancouver
1.
Vansteenkiste J, De Leyn P, Deneffe G, Lievens Y, Nackaerts K, Van Raemdonck D, et al. Vindesine-ifosfamide-platinum (VIP) induction chemotherapy in surgically staged IIIA-N2 non-small-cell lung cancer: a prospective study. ANNALS OF ONCOLOGY. 1998;9(3):261–7.
MLA
Vansteenkiste, JF, PR De Leyn, GJ Deneffe, et al. “Vindesine-ifosfamide-platinum (VIP) Induction Chemotherapy in Surgically Staged IIIA-N2 Non-small-cell Lung Cancer: a Prospective Study.” ANNALS OF ONCOLOGY 9.3 (1998): 261–267. Print.